Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide is a synthetic small molecule belonging to the class of n-benzylpiperidines. It has a molecular formula of C18H27BrN2O3S and a molecular weight of approximately 431.39 g/mol[1][2][6]. The compound is listed as an experimental drug candidate and does not have any approved therapeutic indications or known clinical use in humans[2][8][9]. There are no published data on its mechanism of action or biological targets; it appears to be primarily used for research purposes in chemical biology and drug discovery screening[6]. No information is available regarding its pharmacological activity, safety profile, or potential therapeutic applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide.